Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 155.17 USD -0.21% Market Closed
Market Cap: 373.6B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Johnson & Johnson
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Non-Reccuring Items
-$7.3B
CAGR 3-Years
-10%
CAGR 5-Years
-38%
CAGR 10-Years
-35%
Bristol-Myers Squibb Co
NYSE:BMY
Non-Reccuring Items
-$16.8B
CAGR 3-Years
-6%
CAGR 5-Years
-151%
CAGR 10-Years
-37%
Pfizer Inc
NYSE:PFE
Non-Reccuring Items
-$10.1B
CAGR 3-Years
-50%
CAGR 5-Years
N/A
CAGR 10-Years
-15%
Merck & Co Inc
NYSE:MRK
Non-Reccuring Items
-$8.1B
CAGR 3-Years
-8%
CAGR 5-Years
-35%
CAGR 10-Years
-13%
Zoetis Inc
NYSE:ZTS
Non-Reccuring Items
-$110m
CAGR 3-Years
-10%
CAGR 5-Years
N/A
CAGR 10-Years
-7%
Eli Lilly and Co
NYSE:LLY
Non-Reccuring Items
-$4.3B
CAGR 3-Years
-44%
CAGR 5-Years
-29%
CAGR 10-Years
-33%
No Stocks Found

Johnson & Johnson
Glance View

Market Cap
373.5B USD
Industry
Pharmaceuticals

Johnson & Johnson, often referred to as J&J, is a global healthcare giant that operates in three main segments: Pharmaceuticals, Medical Devices, and Consumer Health Products. Founded in 1886, the company has built a strong reputation for its innovative products, which range from life-saving prescription medications to everyday consumer items such as Band-Aids and Tylenol. With a commitment to improving health and well-being, J&J has consistently invested in research and development, yielding a robust pipeline of drugs and technologies that address critical health challenges, including oncology, immunology, and infectious diseases. This ongoing innovation positions the company favorably in a competitive landscape, ensuring sustained revenue growth and profitability. For investors, Johnson & Johnson represents a compelling opportunity not only due to its diversified business model but also its robust financial health. The company boasts a history of steady revenue growth, strong cash flow generation, and a reliable dividend, making it a perennial favorite for income-focused investors. While it has faced some legal challenges and market pressures, J&J’s ability to adapt and respond to these issues has underscored its resilience. With a strong balance sheet and a global footprint in the ever-growing healthcare sector, Johnson & Johnson continues to demonstrate why it is often regarded as a cornerstone investment in a well-rounded portfolio.

JNJ Intrinsic Value
159.74 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is Johnson & Johnson's Non-Reccuring Items?
Non-Reccuring Items
-7.3B USD

Based on the financial report for Sep 29, 2024, Johnson & Johnson's Non-Reccuring Items amounts to -7.3B USD.

What is Johnson & Johnson's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 10Y
-35%

Over the last year, the Non-Reccuring Items growth was 24%. The average annual Non-Reccuring Items growth rates for Johnson & Johnson have been -10% over the past three years , -38% over the past five years , and -35% over the past ten years .

Back to Top